Plasma concentrations of risperidone and 9-hydroxyrisperidone: Effect of comedication with carbamazepine or valproate

Therapeutic Drug Monitoring

Volumn 22, Issue 4, 2000, Pages 481-485

  Spina, Edoardo ^a,d   Avenoso, Angela ^a   Facciolà, Gabriella ^a   Salemi, Monica ^a   Scordo, Maria G ^a   Giacobello, Tiberio ^a   Madia, Aldo G ^b   Perucca, Emilio ^c  

^a UNIVERSITY OF MESSINA   (Italy)

^b USL 5   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

9 Hydroxyrisperidone; Carbamazepine; CYP3A4; Drug interaction; Risperidone; Valproic acid

Indexed keywords

CARBAMAZEPINE; RISPERIDONE; VALPROIC ACID;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MONITORING; FEMALE; HUMAN; ITALY; MALE; PRIORITY JOURNAL; PSYCHOSIS;

ADULT; ANTIPSYCHOTIC AGENTS; CARBAMAZEPINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PYRIMIDINES; RISPERIDONE; VALPROIC ACID;

EID: 0033853419     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200008000-00019     Document Type: Article

References (28)

1. Biochemical profile of risperidone, a new antipsychotic
2. Clinical review of risperidone
3. New developments in the pharmacologic treatment of schizoaffective disorder
4. Antipsychotic agents and bipolar disorder
5. Absorption, metabolism and excretion of risperidone in humans
6. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects
7. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochrome P450 2D6 and 3A4
8. Survey on pharmacodynamics of the new antipsychotic risperidone
9. The regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the rat
10. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man
11. Relationships between therapeutic dose and serum levels of risperidone and active metabolite in geriatric patients
12. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone
13. Pharmacokinetics and drug interactions: Updates for new antipsychotics
14. Serum concentrations and side effects in psychiatric patients during risperidone therapy
15. Therapeutic drug monitoring of risperidone using a new rapid HPLC method: Reappraisal of interindividual variability factors
16. Serum concentrations and clinical effects of risperidone in schizophrenic patients in Singapore: A preliminary report
17. Mood stabilizer combinations: A review of safety and efficacy
18. Risperidone and cytochrome P4503A
19. A pilot study on risperidone metabolism: The role of cytochromes P450 2D6 and 3A
20. Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity
21. Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs
22. Clinically significant pharmacokinetic drug interactions with carbamazepine: An update
23. Pharmacologic interactions between valproate and other drugs
24. Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate
25. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders
26. The influence of enzyme induction on polymorphic sparteine oxidation
27. Biotransformation
28. Risperidone-carbamazepine interactions: Is cytochrome P450 3A involved?